MabCure gains on ovarian cancer test data

MabCure Inc. (OTCBB:MBCI) gained $0.19 (54%) to $0.54 on Tuesday after reporting that its ovarian cancer test had 94% sensitivity and 100% specificity for diagnosing ovarian cancer. The analysis inclu...